Comparison of outcomes of radical prostatectomy with and without adjuvant pelvic irradiation in patients with pathologic stage C (T3N0) adenocarcinoma of the prostate

被引:10
|
作者
Petrovich, Z
Lieskovsky, G
Langholz, B
Bochner, B
Formenti, S
Streeter, O
Skinner, DG
机构
[1] USC, Sch Med, Dept Radiat Oncol, Los Angeles, CA 90033 USA
[2] USC, Sch Med, Dept Urol, Los Angeles, CA 90033 USA
[3] USC, Sch Med, Dept Prevent Med, Los Angeles, CA 90033 USA
关键词
prostate cancer; prostatectomy; adjuvant radiotherapy;
D O I
10.1097/00000421-199908000-00001
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Patients with localized adenocarcinoma of the prostate gland (CaP) are frequently (similar to 50%) found at radical prostatectomy to have extracapsular disease or positive surgical margins. The management of these patients is a subject of controversy because some question the impact of this manifestation of CaP on patient survival or disease-free survival. Between 1976 and 1991, 241 patients with pathologic stage C (T3N0) were treated in this medical center. Of these 241 patients, 201 (83%) received a planned postoperative pelvic irradiation consisting of 48 Gy given to the prostatic fossa, whereas 40 (17%) patients were treated with radical prostatectomy alone. The two study urologists selected these patients not to receive postoperative irradiation based on intraoperative findings and important prognostic factors. Comparison of treatment outcomes in these two treatment groups is a subject of this report. The 201 patients treated with surgery-radiotherapy (S+RT) combination had a higher pathologic stage, greater incidence of seminal vesicle involvement, p = 0.002, and higher mean and median preoperative prostate-specific antigen level, p < 0.0001, than the 40 surgery (S) alone patients. There was no significant difference in the incidence of higher Gleason's score by the treatment group, p = 0.14. In univariate analysis, there was no significant difference in survival, disease-free survival, and time to failure between the two treatment groups. Tn multivariate analysis after controlling for pathologic stage and Gleason's score, the 201 adjuvant radiotherapy patients were predicted to have recurrence at 68% (95% confidence interval 39%-118%) the rate of the 40 surgery-alone patients. Local recurrence with or without metastatic disease was found in 10% of surgery-alone patients as compared to 5% in those also receiving postoperative irradiation. Treatment tolerance was very good with minor radio-therapy complications only. There was no significant difference in the incidence of incontinence between the two treatment arms. In summary: (a) The use of moderate-dose postoperative radiotherapy was of low toxicity and it did not increase the incidence of incontinence. (b) Local recurrence was 5% in St-RT and 10% in S-alone patients. (c) In multivariate analysis, S+RT patients had 68% rate of recurrence of S-alone patients. (d) Adjuvant RT probably reduces the risk of recurrence in patients with poor prognostic factors. (e) These data need to be interpreted with caution because of the nonrandomized nature of the study.
引用
收藏
页码:323 / 331
页数:9
相关论文
共 50 条
  • [1] Nonrandomized comparison of surgery with and without adjuvant pelvic irradiation for patients with pT3N0 adenocarcinoma of the prostate
    Petrovich, Z
    Lieskovsky, G
    Langholz, B
    Huberman, M
    Streeter, O
    Skinner, DG
    [J]. AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2001, 24 (06): : 537 - 546
  • [2] Adjuvant radiotherapy in patients with pathologic stage C (pT3N0) adenocarcinoma of the prostate
    Petrovich, Z
    Lieskovsky, G
    Langholz, B
    Bochner, B
    Formenti, S
    Streeter, O
    Skinner, DG
    [J]. UROLOGY, 1999, 53 (06) : 1184 - 1193
  • [3] Outcomes of unselected patients with pathologic T3N0 rectal cancer
    Kennecke, Hagen
    Lim, Howard
    Woods, Ryan
    McGahan, Colleen E.
    Hay, John
    Raval, Manoj J.
    Johal, Balvinder
    [J]. RADIOTHERAPY AND ONCOLOGY, 2012, 105 (02) : 214 - 219
  • [4] The results of radical retropubic prostatectomy and adjuvant therapy for pathologic stage C prostate cancer
    Schild, SE
    Wong, WW
    Grado, GL
    Halyard, MY
    Novicki, DE
    Swanson, SK
    Larson, TR
    Ferrigni, RG
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1996, 34 (03): : 535 - 541
  • [5] Radical prostatectomy and postoperative irradiation in patients with pathological stage C (T3) carcinoma of the prostate
    Petrovich, Z
    Lieskovsky, G
    Langholz, B
    Formenti, S
    Baert, L
    Streeter, O
    Skinner, DG
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1998, 40 (01): : 139 - 147
  • [6] BILATERAL PELVIC LYMPHADENECTOMY AND RADICAL RETROPUBIC PROSTATECTOMY FOR STAGE-C ADENOCARCINOMA OF PROSTATE
    ZINCKE, H
    UTZ, DC
    BENSON, RC
    PATTERSON, DE
    [J]. UROLOGY, 1984, 24 (06) : 532 - 539
  • [7] Is Adjuvant Chemotherapy Necessary in the Management of Clinically Staged T3N0 Rectal Adenocarcinoma?
    Sujatha-Bhaskar, Sarath
    Inaba, Colette S.
    Koh, Christina
    Jafari, Mehraneh D.
    Mills, Steven D.
    Carmichael, Joseph C.
    Stamos, Michael J.
    Pigazzi, Alessio
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS, 2017, 225 (04) : S41 - S41
  • [8] SURGERY WITH ADJUVANT IRRADIATION IN PATIENTS WITH PATHOLOGICAL STAGE-C ADENOCARCINOMA OF THE PROSTATE
    PETROVICH, Z
    LIESKOVSKY, G
    FREEMAN, J
    LUXTON, G
    GROSHEN, S
    FORMENTI, S
    BAERT, L
    CHEN, SC
    SKINNER, DG
    [J]. CANCER, 1995, 76 (09) : 1621 - 1628
  • [9] Endocrine therapy with or without radical prostatectomy for T1b-T3N0M0 prostate cancer
    Homma, Y
    Akaza, H
    Okada, K
    Yokoyama, M
    Usami, M
    Hirao, Y
    Tsushima, T
    Sakamoto, A
    Ohashi, Y
    Aso, Y
    [J]. INTERNATIONAL JOURNAL OF UROLOGY, 2004, 11 (04) : 218 - 224
  • [10] Timing and patterns of recurrences and deaths from prostate cancer following adjuvant pelvic radiotherapy for pathologic stage T3/4 adenocarcinoma of the prostate
    Anscher, M. S.
    Clough, R.
    Robertson, C. N.
    Prosnitz, L. R.
    Dahm, P.
    Walther, P.
    Donatucci, C. F.
    Albala, D. M.
    Febbo, P.
    George, D. J.
    Sun, L.
    Moul, J. W.
    [J]. PROSTATE CANCER AND PROSTATIC DISEASES, 2006, 9 (03) : 254 - 260